Managing Treatment-Related Diarrhea in Patients With EGFR-Mutated NSCLC

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Alectinib exhibited a CNS DFS improvement, with a 63% reduction in the risk of this event, and 4-year CNS DFS rate was 90.4% vs 76.1% with chemotherapy.

Retrospective cohort findings may inform tailored treatment approaches for frontline metastatic BRAF V600E–mutated non–small cell lung cancer.